“…Immunohistochemical demonstration of neuroendocrine features (di Sant'Agnese & de Mesy Jensen, 1987;Cohen et al, 1991), c-erbB-2 protein (Gullick et al, 1991;Reilly et al, 1991;Hale et al, 1992), p53 protein (Porter et al, 1992), prostate acid phosphatase (PAP) (Sakai et al, 1991), prostate-specific antigen (PSA) (Hammond et al, 1989;Bazinet et al, 1992) and vimentin (Leong et al, 1988) has been related to tumour prognosis. However, at present there is no general agreement concerning the best combination of prognostic factors.…”